Environmental estrogen mimics, including metalloestrogens that can activate estrogen receptor-alpha (ERα), may contribute to breast cancer risk. However, the underlying mechanisms through which these molecular mimics activate the estrogen receptor-alpha are generally, poorly understood. With concern to this important question, we 
Introduction
Estrogen receptor-α (ERα) is a ligand inducible transcription factor that belongs to the superfamily of nuclear receptors (1) . Upon hormone binding, ERα is activated and regulates the transcription of target genes. Similar to other nuclear receptors, ERα is divided into regions A through F (2) . The N-terminal A/B region harbors transactivation function-1 (AF-1) that plays a role in ligand dependent and independent activation of the receptor. Region C is the DNA binding domain and region D is the hinge region. Region E is the hormone, or ligand, binding domain (LBD). It is responsible for ligand dependent activation of transactivation function-2 (AF-2). It is also important for dimerization and binds coactivators and corepressors (3) . In the absence of hormone, ERα is associated with a complex containing heat shock proteins that render the receptor inactive. Upon hormone binding, a conformational change occurs in the LBD that results in the dissociation of the heat shock complex and the formation of the AF-2 domain (4).
Hormone binding also results in the phosphorylation of serines in the A/B region that increases the activity of AF-1 (5, 6) .
Activation of signal transduction pathways also activates ERα (7) (8) (9) , yet, the mechanisms are not fully understood. Growth factors, such as epidermal growth factor (EGF) and insulin like growth factor-1, activate the Ras-Raf-MEK-MAPK kinase and PI3K-AKT pathways resulting in the phosphorylation of serines in the N-terminal A/B region of the receptor (10) . Although phosphorylation of the A/B region is thought to be responsible for the activation of the AF-1 function, it does not account for the conformational changes necessary for the activation of the AF-2 function in the C-4 terminal LBD suggesting that additional intracellular events are required for the cross talk between signal transduction pathways and ERα.
Metalloestrogens are metals that activate ERα in the absence of estradiol.
Metalloestrogens fall into two subclasses, anions and bivalent cations that include cadmium (11) (12) (13) (14) (15) (16) (17) . The ability of metalloestrogens to activate ERα is due to their ability to form a high affinity complex with the LBD of the receptor (13) (14) (15) (16) . Cadmium and calcium have similar properties (18) and cadmium replaces calcium in biological assays/systems (18) (19) (20) suggesting that metalloestrogens may mimic calcium and that calcium is an intracellular ligand of the LBD. The results of this study suggest that calcium mediates the cross talk between signal transduction pathways and the LBD of ERα.
Materials and Methods

Tissue culture
MCF-7 and MCF-7/LCC cells were obtained from the Tissue Culture Shared
Resource, Georgetown University and authenticated by the resource using short tandem repeat profiling (PowerPlex 1.2, Promega) in March and October 2010. MCF-7 cells were grown as previously described (21) . Two days prior to treatment, the medium was changed to phenol red-free IMEM supplemented with fibronectin, glutamine, HEPES, and transferrin. For calcium treatments, the media was changed to calcium-and phenol red-free DMEM supplemented with 5% charcoal stripped calf serum (CCS). MCF-7/LCC2 cells were grown in phenol red-free IMEM with 5%CCS and treated in phenol red-free IMEM. 
Real time RT-polymerase chain reaction
The real time RT-PCR assay was performed as described (21) . The reaction contained 1ug cDNA, Universal Master Mix, and Assay on Demand. The samples were run on the 7900HT and the data were analyzed by the 2 -Ct method using the SDS 2.1 software (Applied Biosystems). Statistical analyses were performed using two-tailed and paired t-tests.
Chromatin immunoprecipitation (ChIP)
The ChIP assay was performed as previously described (21) . Briefly, the cells were treated with formaldehyde, washed with PBS, and disrupted by sonication. The ERα was immunoprecipitated (H-184, Santa Cruz Biotech), the crosslink was reversed, and the amount of DNA was measured with a PCR assay.
Transient transfection
COS-1 cells (75,000/well) were plated in phenol red-free IMEM supplemented with 5%CCS and transfected with 2μg DNA containing 0.15μg ERα or ERα mutants (2, (22) (23) (24) (25) , 1.5μg ERE-chloramphenicol acetyl transferase (CAT) construct, 0.07μg ȕ-galactosidase, 7.5μl Superfect (Quigen), and 75μl phenol red-free IMEM media and 400μl IMEM with 5%CCS. As a control, cells were transfected with glucocorticoid receptor (GR) and MMTV-CAT. The media was replaced 3-4 hours later and changed to phenol red-free IMEM with 5%CCS 18-20 hours after transfection. Cells were treated in phenol red-free IMEM for 24 hours. The CAT and ȕ-galactosidase assays were conducted as described (21) . Statistical analyses were performed using paired and unpaired t-tests for the wild type and mutants, respectively. 
Site-directed mutagenesis
To generate the mutants D351A, E419A and E423A, QuikChange®XL Site Directed Mutagenesis (Stratagene) was used. Briefly, the reaction contained 10ng of pRER (22) , 100ng/μl primers, 5μl 10x reaction buffer, 1μl dNTP mix, and 1μl
PfuTurbo® DNA polymerase (2.5U/ȝl). For the D351A mutant, the forward 
Binding assay
Binding assays were performed using purified recombinant full length (375.8x10 
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calculated by subtracting non-specific binding from total binding and the binding affinity was determined by nonlinear regression analysis (Prism, GraphPad Software Inc).
Molecular modeling of calcium into potential binding sites
Model construction, visualization, analysis, and molecular dynamics were performed as previously described (21) . The calcium motif and the histidine, glutamate, aspartate, asparagine, and cysteine side chain residues were used in the identification of the cation binding sites. Models were constructed with calcium docked manually into different binding sites. Final model building was carried out using the restrained molecular dynamics simulations where the optimum van der Waals and H-bond distance constraints were set between the calcium cation and the potential binding site residues.
The quality of the models was checked by comparison of coordination geometry with the representative models of calcium-binding proteins from the PDB database. Binding models were energy minimized followed by 25 ps molecular dynamics simulations using DISCOVER.
In vacuo molecular dynamics simulations followed by energy minimizations on such dimolecular complex produced trigonal coordination geometries.
The hydrogen bond distances between calcium and the side chains ranged from 2.5-3.0Å.
Results
Effects of intracellular calcium on ERα activity in MCF-7 cells
To ask whether calcium mediates the cross talk between signal transduction pathways and ERα, several approaches were taken to increase intracellular calcium 
Effects of EGF and calcium on the activation of ERα
To ask whether EGF and calcium activate the N-terminal AF-1 and/or C-terminal AF-2 domains of ERα, transient transfections were conducted with the HE15 construct that contains the AF-1 and DNA binding domains and the HE19 construct that contains the DNA and ligand binding domains ( 
Treatment with EGF resulted in approximately 3.2-fold increase in CAT activity that was blocked by both the antiestrogen and the PLCγ inhibitor while treatment with calcium resulted in approximately in 3.2-fold induction of CAT activity that was blocked by the antiestrogen. Calcium also increased CAT activity with a time course similar to estradiol (Fig.S4) . The GR is not activated by signal transduction pathways (9) 
Interaction of calcium with ERα LBD
To ask whether calcium binds to ERα, purified recombinant human ERα was incubated with varying concentrations of 45 Ca in the absence and presence of a 100-fold 
12 molar excess of CaCl 2 to determine total and non-specific binding, respectively. The binding affinity was determined by nonlinear regression analysis (Fig.4A) . The dissociation constant for calcium was approximately 1.0x10 -6 M (±0.4x10 -6 M, n=2). To ask whether calcium binds to the LBD, the binding assay was repeated with purified recombinant LBD (Fig.4B) 
Effects of calcium on the activation of ERα LBD
Several major structural changes are thought to occur upon activation of the LBD and E542A/D545A suggesting that specific amino acids on helices H4, H10, H11, and H12 and in loop11-12 are necessary for calcium activation of ERα.
Molecular modeling of potential calcium binding sites in ERα LBD
Based on the mutational analysis, the crystal structure of the LBD (PDB:3ERD) (29) , and the chemical properties of calcium, molecular modeling identified four potential binding sites for calcium on the solvent accessible surface of the LBD. Site A, located at the interface of helices H10 and H11, is formed by a direct interaction of calcium with the side chain imidazole group of his516 on helix H10 and with the side chain carboxyl groups of asn519 at the interface of helices H10 and H11 and glu523 on helix H11 (Fig.5A ). Site B, located at the C-terminal end of helix H11, is formed by a direct interaction of the cation with the back bone carboxyl groups of lys529 on helix H11 and The mammary gland is a unique organ that, in addition to utilizing calcium as a second messenger, transports and concentrates the cation for milk production. There is increasing evidence that deregulation of calcium metabolism in the gland is linked to breast cancer (33) . Women diagnosed with hypercalcemia, hypercalcemia associated with hyperparathyroidism, and idiopathic hypercalciurea have an increased risk of developing breast cancer (34) (35) (36) (37) (38) (39) (40) . In patients, metastases overexpress the calcium sensing receptor (41, 42) . In breast cancer cells, the plasma membrane calcium-ATPase is overexpressed (43) and inhibition of the plasma membrane calcium-ATPase (44) 
16 bends towards helix H4 and the core of the pocket (47,49) which, in turn, causes helix H11 to rotate around its axis and tilt away from the pocket to form a continuous bent helix with helix H10 (Fig.6B) . Together with helices H8 and H9, helix H10/H11 forms the dimerization domain. The repositioning of helix H11 also results in the repositioning of helix H12 over the binding pocket. The repositioning of helices H12 and H3 ultimately results in the formation of a shallow hydrophobic groove that constitutes the AF-2 domain, the binding site for coactivators. In addition to inducing major structural changes, estradiol and the agonist diethylstilbestrol (DES) form a cooperative network of van der Waals interactions with hydrophobic amino acids on helices H3, H5, H7, and H11 and in the turn between the β sheets (4,29,48) resulting in one to two additional turns at the ends of helices H3, H8, H11 and H12 (29) .
In proteins, metals such as calcium have different functions including the stabilization of protein structure through interactions with different amino acids. In the case of calcium and ERα, the identification of potential binding sites at the ends of helices H10, H11, and H12 suggests a model (Fig.6C) indirectly activates the receptor, e.g., by the recruitment of coactivators. The mechanism by which calcium activates the LBD of ERα remains to be established.
The ability of calcium to mediate the effects of EGF and other activators of signal transduction pathways on the AF-2 domain provides a rationale basis for the ability of metalloestrogens to activate ERα. Bivalent metals such as cadmium, chromium, cobalt, copper, lead, mercury, nickel, and tin activate ERα due to their ability to form a high affinity complex with the LBD (13-16) . Similar to calcium, these metals require glu523, asp538, and cys381 to activate ERα suggesting that metalloestrogens mimic a physiological activator of the receptor.
Figure Legends
Figure1. Effects of EGF and calcium on ERα target genes.
MCF-7 cells were treated for 24 hours with estradiol (1nM), EGF (150ng/ml; A, B), ATP (100uM; C), and calcium (5mM; D) in the presence and absence of the EGF receptor inhibitor AG1478 (1uM), the calcium chelator BAPTA (1uM), the antiestrogen ICI-182,780 (500nM), the PLC inhibitor U73122 (2 ȝM), or the intracellular calcium chelator BAPTA-AM (1uM). The amount of PgR and pS2 mRNA was measured using a real time RT-PCR assay and normalized to the amount of 18S ribosomal RNA for EGF and ATP treatments or GAPDH mRNA for calcium treatments. Data are expressed as percent control (mean±SD; three independent experiments). *, p < 0.05; **; p < 0.005; ***, p < 0.0005. a, compared to control; b, compared to treatment.
Figure2. Effects of EGF and calcium on ERα activity
A. Effects of EGF and calcium on ERα activity in MCF-7 cells. Cells were treated for 1 hour with estradiol (1nM), calcium (5mM), or EGF (150ng/ml) and the occupancy of ERα on the pS2 promoter was examined using a chromatin immunoprecipitation assay.
B. Effects of calcium on growth.
Cells treated with estradiol (1nM) and calcium (0.25, 0.5, 1.0, and 2.0mM) on day 0 or calcium (0.25, 0.5, and 1.0mM) on days 0, 1, 2 and 3 in the presence and absence of the antiestrogen ICI-182,780 (500nM). Cell number was measured on day 4 (mean±SD; three independent experiments). *, p < 0.05; **; p < 0.005; ***, p < 0.0005. a, compared to control; b, compared to treatment. 
C. Effects of EGF and calcium on ERα target genes in MCF-
